Trial Profile
A randomized, double-blind, placebo-controlled multi-centre phase II study to evaluate efficacy and tolerability of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Alendronic acid/guanidine dextran conjugate (Primary)
- Indications Prostate cancer
- Focus Biomarker; Pharmacodynamics
- Sponsors DexTech Medical
- 29 Jun 2016 Status changed from recruiting to discontinued.
- 03 Jan 2015 New trial record